MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Ambrx Biopharma Inc (NASDAQ: AMAM)
Organization & Developments: Ambrx
Parents
Ambrx Biopharma Inc (NASDAQ: AMAM)
Children
*Ambrx develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance.
*Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code
*Protein Medicinal Chemistry™
*Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties.
2022: Ambrx cuts 15% of staff and dumps lead HER2 asset after 'strategic review'
2022: Biotech layoffs continue as Ambrx cuts staff and part of its pipeline to extend its cash
2022: Meet the Biotech Stock That Jumped Over 1000% in One Day_ yahoo
2023: Ambrx Biopharma: Potential With Recently Released Prostate Cancer Data (NASDAQ:AMAM)
2023: Ambrx: Next-Generation Antibody-Drug Conjugates, Buying The Dip After ESMO Data
2024: Ambrx Announces Sale to Johnson & Johnson
2024: Johnson & Johnson's Acquisition Of Ambrx Biopharma: Hold Through It_ seekingalpha.com
8. Ambrx
Jumps
*Key People: Ambrx
Finance & Acquisitions: Ambrx